Partners & Customers
10About Onxeo
Onxeo (Paris: ONXEO) is a developer of orphan oncology drugs. The company is focused on developing therapeutics for rare cancers, one of the fastest growing markets in the healthcare industry with high, unmet medical needs. Onxeo's comprehensive portfolio features a broad orphan oncology pipeline, with three independent programs in advanced clinical development, including Onxeo's first approved orphan oncology drug, Beleodaq.

Want to inform investors similar to Onxeo about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Onxeo News
Jan 27, 2023
Photo/Shutterstock French biotech company Onxeo S.A. has given an update on the clinical development program of its first-in-class drug candidate AsiDNA. Onxeo has activated its first U.S. clinical study site, Next Oncology San Antonio. This phase 1b/2 multicenter, basket trial intends to assess the safety and preliminary activity of AsiDNA in combination with olaparib in patients with recurrent ovarian, breast and metastatic castration-resistant prostate cancer (mCRPC) who have progressed on previous PARP inhibitor therapy. The primary endpoint of the study will assess the safety and tolerability of the combination as well as to determine the recommended phase 2 dose. Key secondary endpoints will assess the preliminary activity and duration of response for the combination. ‘Important next step’ Shefali Agarwal, chairwoman of the board of directors and CEO, said: “We are delighted with the initiation of this important clinical trial in the U.S. to further explore the potential of our first-in-class drug candidate, AsiDNA. This investigational product has been in clinical development in Europe for the last few years, in recurrent solid tumors. In clinical studies AsiDNA appears to be well tolerated with encouraging clinical activity in the studied patients till date. The activation of this first study in the U.S. is an important next step towards its global clinical development. “The recent encouraging activity observed from the preliminary data in the REVOCAN study indicates the potential of AsiDNA to re sensitize patients to PARP therapy which potentially addresses an unmet need and could meaningfully impact patients living with recurrent ovarian cancer who have progressed on an initial treatment with a PARP inhibitor. “Additionally, this lays a strong foundation for our next first in class drug candidate OX425 which is sourced from the same proprietary PlatON platform and is a PARP/DDR specific decoy agonist thereby possibly not inducing tumor resistance to treatment. This profile represents a potential differentiation in safety and activity from other targeted therapies such as PARP inhibitors and we are on track to file an IND in mid- 2023.” Content continues below
Onxeo Acquisitions
3 Acquisitions
Onxeo acquired 3 companies. Their latest acquisition was DNA Therapeutics on February 29, 2016.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
2/29/2016 | Seed / Angel | $1.1M | Acquired | 2 | ||
5/22/2014 | Series C | |||||
5/22/2014 |
Date | 2/29/2016 | 5/22/2014 | 5/22/2014 |
---|---|---|---|
Investment Stage | Seed / Angel | Series C | |
Companies | |||
Valuation | |||
Total Funding | $1.1M | ||
Note | Acquired | ||
Sources | 2 |
Onxeo Partners & Customers
10 Partners and customers
Onxeo has 10 strategic partners and customers. Onxeo recently partnered with Institut Curie on September 9, 2022.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
9/1/2022 | Partner | France | Shefali Agarwal , Onxeo S.A. 's President and Chief Executive Officer , stated : `` Onxeo S.A. is proud of its clinical collaboration with Institut Curie , and would like to thank Professor François Doz -- the study 's lead investigator -- for his involvement in this project . | 2 | |
2/4/2021 | Partner | France | Institut Curie and Onxeo S.A. collaborated on this multi-center phase 1b/2 trial design . | 1 | |
4/16/2020 | Licensee | United States | Onxeo S.A.’s $6.6 Million Agreement with Acrotech Biopharma LLC Onxeo S.A. , a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response , in particular against rare or resistant cancers , announced that it has entered into agreements with Acrotech , a wholly-owned subsidiary of Aurobindo Pharma , which extend Acrotech 's rights to belinostat , to all territories not previously covered under Onxeo S.A. 's prior agreement with Acrotech as well as transfer certain IP and know-how related to belinostat in all its forms . | 1 | |
1/29/2020 | Partner | ||||
4/24/2017 | Licensee |
Date | 9/1/2022 | 2/4/2021 | 4/16/2020 | 1/29/2020 | 4/24/2017 |
---|---|---|---|---|---|
Type | Partner | Partner | Licensee | Partner | Licensee |
Business Partner | |||||
Country | France | France | United States | ||
News Snippet | Shefali Agarwal , Onxeo S.A. 's President and Chief Executive Officer , stated : `` Onxeo S.A. is proud of its clinical collaboration with Institut Curie , and would like to thank Professor François Doz -- the study 's lead investigator -- for his involvement in this project . | Institut Curie and Onxeo S.A. collaborated on this multi-center phase 1b/2 trial design . | Onxeo S.A.’s $6.6 Million Agreement with Acrotech Biopharma LLC Onxeo S.A. , a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response , in particular against rare or resistant cancers , announced that it has entered into agreements with Acrotech , a wholly-owned subsidiary of Aurobindo Pharma , which extend Acrotech 's rights to belinostat , to all territories not previously covered under Onxeo S.A. 's prior agreement with Acrotech as well as transfer certain IP and know-how related to belinostat in all its forms . | ||
Sources | 2 | 1 | 1 |
Onxeo Team
2 Team Members
Onxeo has 2 team members, including , .
Name | Work History | Title | Status |
---|---|---|---|
Gilles Avenard | Sanofi, and LFB Biomedicaments | Founder | Current |
Name | Gilles Avenard | |
---|---|---|
Work History | Sanofi, and LFB Biomedicaments | |
Title | Founder | |
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.